Roche Seeks To Increase Holding In Chugai To 59.9 Percent
This article was originally published in PharmAsia News
Roche plans to buy nearly 10 percent more of Japan's Chugai Pharmaceutical. Roche's plan is to boost its 50.1 percent stake in Chugai to 59.9 percent through a one-month tender offer to shareholders. The two companies have been tied for several years through an alliance that led to Roche turning Chugai into a subsidiary. The original 2001 agreement gave Roche the option of increasing its holdings to 59.9 percent after six years. (Click here for more - a subscription may be required
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.